-$0.10 Earnings Per Share Expected for Viking Therapeutics Inc (VKTX) This Quarter

Analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to post ($0.10) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Viking Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.09). Viking Therapeutics reported earnings of ($0.14) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The company is expected to issue its next earnings results on Wednesday, March 6th.

According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.45) to ($0.40). For the next financial year, analysts expect that the business will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.34). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.01.

Several equities research analysts recently commented on the stock. Maxim Group reiterated a “buy” rating and issued a $28.00 price objective on shares of Viking Therapeutics in a research report on Thursday, November 8th. Raymond James reiterated an “outperform” rating and issued a $43.00 price objective (up from $15.00) on shares of Viking Therapeutics in a research report on Tuesday, September 18th. Roth Capital boosted their price objective on shares of Viking Therapeutics from $13.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 19th. BidaskClub lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 3rd. Finally, William Blair reiterated a “market perform” rating on shares of Viking Therapeutics in a research report on Monday, October 1st. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $28.00.

Viking Therapeutics stock opened at $11.29 on Friday. Viking Therapeutics has a 52 week low of $2.53 and a 52 week high of $24.00. The stock has a market capitalization of $806.78 million, a P/E ratio of -14.29 and a beta of 2.92.

In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in VKTX. Quantbot Technologies LP purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth about $109,000. First Mercantile Trust Co. purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth about $131,000. Janney Montgomery Scott LLC purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth about $114,000. Man Group plc purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth about $211,000. Finally, Strs Ohio purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth about $120,000. Institutional investors own 62.34% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Featured Story: Different Types of Derivatives

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit